9 assets in Fallopian Tube Mucinous Adenocarcinoma

Therapeutic assets addressing Fallopian Tube Mucinous Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Carboplatin Fallopian Tube Mucinous Adenocarcinoma	Ohio State University Comprehensive Cancer Center	P3	BBB (74)
Cis-Diamminedichloroplatinum Ii Fallopian Tube Mucinous Adenocarcinoma	Ohio State University Comprehensive Cancer Center	P3	BB (70)
Adriamycin Fallopian Tube Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (60)
Docetaxel Fallopian Tube Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P3	B (60)
Cediranib Fallopian Tube Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	B (59)
Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter Fallopian Tube Mucinous Adenocarcinoma	Mayo Clinic	P2	B (59)
Durvalumab Fallopian Tube Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nogitecan Fallopian Tube Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Fallopian Tube Mucinous Adenocarcinoma	National Cancer Institute (NCI)	P2	CCC (53)